🇺🇸 FDA
Patent

US 12215133

GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

granted A61KA61K38/00A61K38/26

Quick answer

US patent 12215133 (GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use) held by BrightGene Bio-Medical Technology Co., Ltd. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BrightGene Bio-Medical Technology Co., Ltd.
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61K38/26, A61P, A61P3/10